Valuation: Cogent Biosciences, Inc.

Market Cap 5.8B 5B 4.73B 4.29B 8.04B 554B 8.09B 56.19B 21.61B 282B 21.78B 21.3B 891B P/E 2026 *
-14.8x
P/E 2027 * -32.3x
Enterprise Value 5.67B 4.88B 4.63B 4.19B 7.86B 542B 7.9B 54.93B 21.12B 276B 21.29B 20.82B 871B EV / Sales 2026 *
947x
EV / Sales 2027 * 19x
Free-Float
99.51%
Yield 2026 *
-
Yield 2027 * -
1 day-1.97%
1 week-3.88%
Current month-4.54%
1 month-10.45%
3 months+0.94%
6 months-1.74%
Current year-5.94%
1 week 33.07
Extreme 33.07
35.75
1 month 33.07
Extreme 33.07
38.62
Current year 30.87
Extreme 30.87
43.39
1 year 11.6
Extreme 11.6
43.73
3 years 3.67
Extreme 3.67
43.73
5 years 3.67
Extreme 3.67
43.73
10 years 3.67
Extreme 3.67
43.73
Manager TitleAgeSince
Chief Executive Officer 50 2020-10-22
Director of Finance/CFO 45 2018-05-31
Chief Tech/Sci/R&D Officer 52 2021-04-05
Director TitleAgeSince
Director/Board Member 68 2018-01-31
Director/Board Member 74 2019-07-25
Director/Board Member 59 2019-07-25
Date Insider Type Main position Quantity % Market Cap. Importance
8/27/26 Exercice

Director

136,530 0.0787%
7/1/26 Free

Director

627 0.0004%
6/9/26 Free

Director

17,901 0.0105%
Change 5-day change 1-year change 3-year change Capi.($)
-1.97%-3.88%+163.90%+190.52% 5.8B
-2.11%-1.68%+43.40%+95.58% 66.93B
+1.90%+0.07%+36.36%+77.26% 61.97B
+1.67%+2.47%-11.32%+392.05% 28.26B
+4.55%+1.36%+26.52%+17.28% 24.59B
+0.34%-6.78%-0.01%-14.59% 24.3B
+1.20%-0.98%+19.17%-21.77% 19.41B
-3.03%-2.29%+181.72%+333.47% 16.77B
+3.44%-1.88%-5.46%+547.21% 14.18B
+3.24%-0.31%-7.34%+833.51% 14B
Average +1.04%-3.04%+44.69%+245.05% 27.62B
Weighted average by Cap. +0.78%-2.85%+35.05%+173.92%

Financials

2026 *2027 *
Net sales 5.99M 5.16M 4.89M 4.43M 8.31M 572M 8.35M 58.03M 22.31M 291M 22.49M 22M 920M 295M 254M 241M 218M 409M 28.17B 411M 2.86B 1.1B 14.33B 1.11B 1.08B 45.28B
Net income -399M -344M -325M -295M -553M -38.11B -556M -3.87B -1.49B -19.39B -1.5B -1.47B -61.27B -199M -172M -163M -148M -277M -19.06B -278M -1.93B -743M -9.7B -749M -733M -30.64B
Net Debt -130M -112M -106M -95.87M -180M -12.39B -181M -1.26B -483M -6.3B -487M -476M -19.91B -206M -178M -168M -152M -286M -19.69B -287M -2B -768M -10.02B -774M -757M -31.65B
Logo Cogent Biosciences, Inc.
Cogent Biosciences, Inc. is a clinical-stage biotechnology company. It is focused on developing precision therapies for genetically defined diseases. Its approach is to design rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its advanced program is bezuclastinib, also known as CGT9486, a highly selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis (SM), a serious and rare disease caused by unchecked proliferation of mast cells. The Company has on-going Phase I studies of its CNS-penetrant, selective mutant ErbB2 inhibitor and its potential best-in-class, wild-type-sparing, PI3Ka inhibitor. In addition, the Company’s research team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in KRAS and JAK2.
Employees
258
Date Price Change Volume
26-09-11 US$33.41 -1.97% 1,715,802
26-09-10 US$34.08 -0.29% 2,264,643
26-09-09 US$34.18 -3.12% 1,587,526
26-09-08 US$35.28 +1.50% 2,244,424
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
33.41USD
Average target price
55.82USD
Spread / Average Target
+67.07%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. COGT Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!